PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of agpsychBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleAnnals of General Psychiatry
 
Ann Gen Psychiatry. 2010; 9(Suppl 1): S102.
Published online 2010 April 22. doi:  10.1186/1744-859X-9-S1-S102
PMCID: PMC2991784

Evaluation of pharmacotherapy in inpatients with mania in bipolar disorder

Background

The studies concerning prophylactic treatment in bipolar disorder suggest it should be introduced after the first manic episode [1]. Also early polytherapy is promoted, mainly mood stabilizers and antipsychotics. Antipsychotics are recommended in short-term use [2], but they are also used after improvement. Typical antipsychotics are effective in monotherapy in 70% of patients, like mood stabilizers.[3] The combination of antipsychotics and mood stabilizers is superior to monotherapy in rapid control of agitation.

Materials and methods

We determined which drugs are chosen at Institute of Psychiatry and Neurology for treating and preventing manic episodes. 61 inpatients diagnosed with manic episodes were evaluated.At discharge, 28% of patient were ordered to take one drug. For 72% patients polytherapy was ordered.

Results

There was no difference in the number of disease or manic phases between the group of patients with a remission phase lasting for at least a year and less than a year. Recurrence within one year after discharge was twice as frequent in patients with polytherapy than with monotherapy. During polytherapy the probability of avoiding recurrnce was dropping quickly.No dependence was observed between the number of recurrences at patients with monotherapy or polytherapy and such parameters as the number of manic episodes, the number of depression episodes or education.

Conclusions

In most inpatients polytherapy was applied. For the maintenance phase of treatment the same drugs were recommended as used for active treatment. The way of treatment fully corresponds to bipolar disorder treatment standards.

References

  • Biel MG, Peselow E, Mulcare L, Case BG, Fieve R. Continuation versus discontinuation of lithum in reccurent bipolar illness:A naturalistic study. Bipolar Disorders. 2007;9:435–442. doi: 10.1111/j.1399-5618.2007.00389.x. [PubMed] [Cross Ref]
  • Mendlewicz J, Souery D, Rivelli SK. Short-term and long-term treatment of bipolar patients: beyond the guidelines. J Affect Dis. 1999;55:79–85. doi: 10.1016/S0165-0327(99)00125-1. [PubMed] [Cross Ref]
  • Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int J Neuopsychopharmacology. 2003;6:277–284. doi: 10.1017/S1461145703003560. [PubMed] [Cross Ref]
  • Hirschfeld R, Calabrese JR, Weissman M, Frye M, Keck PE, Wagner K, Reed M. Prevalence of bipolar spectrum in US adults [abstract] European Neuropsychopharmacology. 2002;12:218. doi: 10.1016/S0924-977X(02)80242-5. [Cross Ref]

Articles from Annals of General Psychiatry are provided here courtesy of BioMed Central